Saturday, July 2, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

A model for predicting the evolution of the Omicron wave

by Medical Finance
in Coronavirus
A model for pedicting the evolution of the Omicron wave
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has threatened many societies worldwide since its emergence.

shutterstock 1703583271

Study: Forecast of Omicron Wave Time Evolution. Image Credit: ZinetroN / Shutterstock.com

Although there remains a lack of sufficient information on the transmission characteristics of this variant, research has shown that the Omicron variant spreads about four times faster than the SARS-CoV-2 Beta variant and has an average doubling time of three days. Current coronavirus disease 2019 (COVID-19) vaccines also appear to be less effective against the Omicron variant as compared to earlier SARS-CoV-2 strains.

In a new COVID study, scientists forecast the temporal evolution of the Omicron wave according to a susceptible-infectious-recovered/removed (SIR) epidemic compartment model with a constant stationary ratio (k) between the infection (a(t)) and recovery rates µ(t).

About the study

Reliable estimates of the maximum and total percentage of infected people are crucial, as they can be compared to available medical facilities in different countries. In the current study, scientists provided estimates of these crucial variables.

The three considered scenarios were referred to as optimistic, pessimistic, and intermediate, and the resulting pandemic parameters for 12 different countries including Italy, Austria, Denmark, Germany, Switzerland, Great Britain, France, Belgium, Netherlands, Russia, Sweden, and the United States were assessed.

The key parameters considered in the SIR model included the maximum rate of new infections, total number of infected persons, peak time, and maximum seven-day incidence per 100,000 individuals.  

Several crucial assumptions were made regarding the stationary ratio (k) and the infection (a(t)) rate. Under the optimistic case, it was assumed that the reduction in the early doubling time of the Omicron variant, as compared to the Beta variant, was driven by a corresponding increase in the initial infection rate a(0), while the k ratio remained the same as the Beta variant. The reverse was assumed for the pessimistic case.

For the intermediate case, it was assumed that the stationary ratio and initial infection rate contributed equally to the decrease in the early doubling time.

Study findings

Among the European countries, Denmark was observed to have the smallest omicron peak time; therefore, the scientists opined that the Danish data may be better explained by the intermediate or pessimistic scenario. In Great Britain, seven-day incidence (SDI) values showed a clear peak of 1,865 on January 7, 2022, which suggested that there were a high number of Omicron infections in this country.

In the case of Germany, researchers forecasted the peak of the wave at 32, 38, and 45 days after the start of the Omicron wave in the optimistic, intermediate, and pessimistic cases, respectively. The corresponding SDI values were 7,090, 13,263, and 28,911, respectively.

The values for Switzerland were quite similar, with peak times including 30, 36, and 42 days after the start of the Omicron wave, and maximum SDI values were observed to be 8,148, 15,060, and 29,259, respectively.

With the starting date being assumed to be January 1, 2022, researchers observed that the peak of the wave was reached between January 31, 2022, and February 13, 2022. They predicted that in the optimistic scenario, the total cumulative number of Omicron infections was expected to be 0.208, but could rise to 0.824 in the pessimistic case. The latter half decay times were predicted to be 3.2 to 3.6 and 5.3 days under the optimistic, intermediate, and pessimistic scenarios, respectively.

The lower hospitalization rate during the Omicron wave is largely driven by the high percentage of vaccinated and boosted individuals within these populations. Thus, the scientists estimated that the German healthcare system would be able to sustain a maximum seven-day incidence of 2,800, which is 2.5 times smaller than the maximum SDI of 7,090 in the optimistic case.

It must be noted that in Germany, the significantly smaller mortality rates as compared to earlier SARS-CoV-2 variants have been supported by lower a hospitalization rate. However, researchers warn that the numbers could be quite different in the less likely pessimistic case.

Conclusions

Motivated by how little is known about the SARS-CoV-2 Omicron variant, scientists used a SIR model with a constant stationary ratio between the infection and recovery rates to forecast the time evolution of this variant.

Three scenarios were considered for twelve countries, with estimates provided on key parameters including the total number of infected persons, maximum rate of new infections, peak time, and maximum seven-day incidence per 100,000 individuals. These estimated numbers ranged in order of magnitude below those which were observed for the SARS-CoV-2 Beta variant.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Association of SARS-CoV-2 Infection with Serious Maternal Morbidity and Mortality From Obstetric Complications. Image Credit: milkumistock / Shutterstock.com

The serious risks COVID-19 may pose during pregnancy

by Medical Finance
July 2, 2022
0

In a recent JAMA study, researchers report on the potential for serious maternal illness or death during or following a pregnancy...

Study: BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine. Image Credit: Tamer Adel Soliman/Shutterstock

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

by Medical Finance
July 2, 2022
0

The ongoing coronavirus disease 2019 (COVID-19) pandemic has severely disrupted the world in terms of the disease burden and...

Study: Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants. Image Credit: Tatiana Shepeleva/Shutterstock

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

by Medical Finance
July 2, 2022
0

The rapid outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide has resulted in the coronavirus disease...

Study: Humoral and cellular immune memory to four COVID-19 vaccines. Image Credit: Telnov Oleksii/Shutterstock

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

by Medical Finance
July 2, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers evaluated the humoral and cellular immune memory induced by...

Study: High neutralizing antibody levels against SARS-CoV-2 Omicron after UB-612 booster vaccination. Image Credit: natatravel/Shutterstock

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

by Medical Finance
July 2, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers evaluated the effectiveness of a novel vaccine candidate UB-612...

Study: Variation of total anti-SARS-CoV-2 antibodies after primary BNT162b2 vaccination and homologous booster. Image Credit: BaLL LunLa/Shutterstock

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

by Medical Finance
July 2, 2022
0

A recent article posted to the Research Square* preprint server presented the differences among total anti-severe acute respiratory syndrome coronavirus 2...

Next Post
Scrapping many Covid testing measures is a grave mistake, says London Medical Laboratory

Cannabidiol found to inhibit SARS-CoV-2 infection in human cells and mice

Scientists discover antibody that inhibits a broad range of sarbecoviruses

Some states still pushing ineffective covid antibody treatments

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. Image Credit: NIAID
    A ferritin nanoparticle candidate vaccine for COVID
  • Study: Cov2clusters: genomic clustering of SARS-CoV-2 sequences. Image Credit: Coffeemill / Shutterstock.com
    Novel method for producing stable genomic clusters of SARS-CoV-2 cases
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply